临床试验状态

Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19

登记停止说明（原文）：The study was planned during COVID-19 outbreak to assess Baricitinib in Patients With Moderate and Severe COVID-19. The study could not be started due to many obstacle which was raised because of Pandemic. The study is no more relevant.

Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus

登记停止说明（原文）：Enrollment closed before the planned 36 eyes were reached because of the limited number of eligible patients and the long recruitment period (July 2024 to December 2025); 20 eyes of 19 participants were enrolled.

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

登记停止说明（原文）：Due to extremely low accrual rate

Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells

登记停止说明（原文）：Suboptimal treatment response

Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

登记停止说明（原文）：FDA Clinical Hold

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia

登记停止说明（原文）：inability to recruit volunteers

Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease

登记停止说明（原文）：The primary reasons for early study termination are administrative and funding issues and inability to obtain the investigational product; this lead to insufficient participant enrollment.

CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia

登记停止说明（原文）：Suboptimal treatment response

CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy

登记停止说明（原文）：Suboptimal treatment response

Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer

登记停止说明（原文）：Dose-finding stage has been completed, and dose-expanding stage was not conducted due to design amendment.

Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia

登记停止说明（原文）：No significant improvement in efficacy was observed.

Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma

登记停止说明（原文）：Sponsor decision based on meeting essential enrollment and obtaining substantial data to support future pancreatic ductal adenocarcinoma (PDAC) trials in a first-line setting.

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer

登记停止说明（原文）：The study was stopped early due to lack of efficacy.

Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)

登记停止说明（原文）：Change in standard of care treatment for muscle-invasive bladder cancer

Incretin Hormones in Type 1 Diabetes Mellitus;Effect of Metformin Treatment

登记停止说明（原文）：It was not conducted due to the emergency restrictive measures implemented during the COVID-19 pandemic, which made it impossible to carry out the patient visits required by the study protocol.

Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)

登记停止说明（原文）：Loss of funding

Long-term Extension of GTX-102 in Angelman Syndrome

登记停止说明（原文）：Lack of efficacy

Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)

登记停止说明（原文）：Lack of efficacy